HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
Sexually and well-being in early menopause. Effect of transdermal estradiol therapy.
BACKGROUND This study focus on the effect of 6 months transdermal estradiol therapy ( TTS ) on the sexual behaviour and the quality of life in early menopausal women , complaining of uncomfortable menopausal symptoms . METHODS Three hundred and sixty-two postmenopausal women , aged 48 - 56 , participated in this study . One hundred and seventy-one of them were given continuous solid matrix patch TTS 50 mg/day for 6 months . Sexual behaviour , menopausal symptoms and well-being were evaluated through a self-rating method . We used a structured question naire with three obligatory answers ( less/same/more ) for each question --sexual life , hot flushes , touchiness , insomnia , blood pressure , work willing , memory loss , well-being -- filled in by the women themselves or by the medical equipe after a telephone interview . RESULTS Seventy five per cent of women aged 51 - 53 and 84 % aged 54 - 56 , who had been treated for 6 months with TTS showed a fall of sexual drive , if compared with , respectively , 62 % and 48 % of untreated subjects . Relief of hot flushes , touchiness and insomnia occurred in 80 % of treated women , with slight differences among the various groups while 61 % showed increase of well-being . CONCLUSIONS The results of our study demonstrate that continuous TTS for 6 months decreased sexual drive in 69 % of women , improved menopausal symptoms in 80 % women but increased well-being only in 61 % of women . These differences suggest that women 's well-being does not seem linked only to the relief of menopausal symptoms and the impairment of their sexual life can play a negative role
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .